



# Ophthalmic Prostaglandins Quantity Limit Program Summary

Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Health Insurance Marketplace, and KeyRx.

## POLICY REVIEW CYCLE

**Effective Date**  
1/1/2024

**Date of Origin**  
1/1/2008

## FDA APPROVED INDICATIONS AND DOSAGE

See package insert for FDA prescribing information: <https://dailymed.nlm.nih.gov/dailymed/index.cfm>

## POLICY AGENT SUMMARY QUANTITY LIMIT

| Target Brand Agent Name(s) | Target Generic Agent Name(s)                 | Strength    | QL Amount | Dose Form  | Day Supply | Duration | Addtl QL Info | Allowed Exceptions                            | Targeted NDCs When Exclusions Exist |
|----------------------------|--|-------------|-----------|------------|------------|----------|---------------|---|-------------------------------------|
|                            | Bimatoprost Ophth Soln 0.03%                 | 0.03 %      | 2.5       | mLs        | 30         | DAYS     |               | Wastage is significant but cannot be avoided. |                                     |
| Iyuzeh                     | latanoprost (pf) ophth soln                  | 0.005 %     | 30        | Containers | 30         | DAYS     |               | Wastage is significant but cannot be avoided. |                                     |
| Lumigan                    | Bimatoprost Ophth Soln 0.01%                 | 0.01 %      | 2.5       | mLs        | 30         | DAYS     |               | Wastage is significant but cannot be avoided. |                                     |
| Travatan z                 | travoprost ophth soln                        | 0.004 %     | 2.5       | mLs        | 30         | DAYS     |               | Wastage is significant but cannot be avoided. |                                     |
| Vyzulta                    | latanoprostene bunod ophth soln              | 0.024 %     | 2.5       | mLs        | 30         | DAYS     |               | Wastage is significant but cannot be avoided. |                                     |
| Xalatan                    | Latanoprost Ophth Soln 0.005%                | 0.005 %     | 2.5       | mLs        | 30         | DAYS     |               | Wastage is significant but cannot be avoided. |                                     |
| Xelpros                    | latanoprost ophth emulsion                   | 0.005 %     | 2.5       | mLs        | 30         | DAYS     |               | Wastage is significant but cannot be avoided. |                                     |
| Zioptan                    | tafluprost preservative free (pf) ophth soln | 0.015 MG/ML | 30        | Containers | 30         | DAYS     |               | Wastage is significant but cannot be avoided. |                                     |

## CLIENT SUMMARY – QUANTITY LIMITS

| Target Brand Agent Name(s) | Target Generic Agent Name(s)                 | Strength    | Client Formulary   |
|----------------------------|--|-------------|--|
|                            | Bimatoprost Ophth Soln 0.03%                 | 0.03 %      | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |
| Iyuzeh                     | latanoprost (pf) ophth soln                  | 0.005 %     | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |
| Lumigan                    | Bimatoprost Ophth Soln 0.01%                 | 0.01 %      | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |
| Travatan z                 | travoprost ophth soln                        | 0.004 %     | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |
| Vyzulta                    | latanoprostene bunod ophth soln              | 0.024 %     | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |
| Xalatan                    | Latanoprost Ophth Soln 0.005%                | 0.005 %     | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |
| Xelpros                    | latanoprost ophth emulsion                   | 0.005 %     | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |
| Zioptan                    | tafluprost preservative free (pf) ophth soln | 0.015 MG/ML | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |

## QUANTITY LIMIT CLINICAL CRITERIA FOR APPROVAL

| Module | Clinical Criteria for Approval  |
|--------|---|
| QL     | <p><b>Quantity limit for the Target Agent(s)</b> will be approved when ONE of the following is met:</p> <ol style="list-style-type: none"> <li>1. The requested quantity (dose) does NOT exceed the program quantity limit <b>OR</b></li> <li>2. The requested quantity (dose) is greater than the program quantity limit AND BOTH of the following: <ol style="list-style-type: none"> <li>A. The requested quantity (dose) is greater than the maximum FDA labeled dose for the requested indication <b>AND</b></li> <li>B. Information has been provided to support therapy with a higher dose for the requested indication</li> </ol> </li> </ol> <p><b>Length of approval:</b> 12 months</p> |

